Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

ObjectiveThe Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features of...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatic & musculoskeletal diseases open 2018-06, Vol.4 (1), p.e000669-e000669
Main Authors: Gladman, Dafna D, Kavanaugh, Arthur, Gómez-Reino, Juan J, Wollenhaupt, Jürgen, Cutolo, Maurizio, Schett, Georg, Lespessailles, Eric, Guerette, Benoit, Delev, Nikolay, Teng, Lichen, Edwards, Christopher J, Birbara, Charles A, Mease, Philip J
Format: Article
Language:English
Subjects:
Arthritis
Biological products
Clinical trials
Drug dosages
Human health and pathology
Life Sciences
Patients
Psoriasis
Psoriatic Arthritis
Rheumatology
Rhumatology and musculoskeletal system
Studies
TNF inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveThe Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features of PsA leading to disability and affecting quality of life. PALACE 1, 2 and 3 data were pooled to assess the efficacy of apremilast on enthesitis and dactylitis outcomes in patients with these conditions at baseline.MethodsPatients with enthesitis (n=945) or dactylitis (n=633) at baseline were analysed after receiving double-blind treatment with placebo, apremilast 30 mg two times per day or apremilast 20 mg two times per day up to 52 weeks and continuing up to 5 years. Data were analysed through 156 weeks. Enthesitis was evaluated by Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and dactylitis via dactylitis count.ResultsAt week 24, patients receiving apremilast 30 mg two times per day demonstrated a significantly greater mean change in enthesitis (−1.3 vs −0.9; p
ISSN:2056-5933
2056-5933
DOI:10.1136/rmdopen-2018-000669